5:22 PM
 | 
Oct 29, 2012
 |  BC Extra  |  Company News

Titan seeks approval for Probuphine

Titan Pharmaceuticals Inc. (OTCBB:TTNP) submitted an NDA to FDA for Probuphine buprenorphine to treat opioid dependence. The company requested Priority Review for the application. The NDA was submitted under...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >